Detail akcie Vanda Pharma online

Business Summary: Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Vanda Pharmaceuticals Inc. revenues increased 9% to $216.1M. Net loss increased from $18.9M to $220.5M. Revenues reflect Fanapt segment increase of 24% to $117.3M. Higher net loss reflects United States segment loss increase from $40.7M to $151.2M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.33 to -$3.74.